

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

		V and the state of		
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/907,007	07/17/2001	Nicholas Kim Hayward	10441B	8056
	990 08/15/2002 OTT, MURPHY & Pl	EXAMINER		
400 Garden City Plaza Garden City, NY 11530			SAOUD, CHRISTINE J	
Gardon Groj, 11			ART UNIT	PAPER NUMBER
			1647 DATE MAILED: 08/15/2002	, <u>Y</u>

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No.

Applicant(s)

09/907,007

HAYWARD et al.

Office Action Summary

Examiner
Christine Saoud

Art Unit **1647**



	The MAILING DATE of this communication appears o	on the cover sheet with the correspondence address			
		i			
THE M - Extensio mailing c - If the pe - If NO pe - Failure t	date of this communication. Ariod for reply specified above is less than thirty (30) days, a reply within the seriod for reply is specified above, the maximum statutory period will apply a oreply within the set or extended period for reply will, by statute, cause the received by the Office later than three months after the mailing date of the preceived by the Office later than three months after the mailing date of the process of the pr	no event, however, may a reply be timely filed after SIX (6) MONTHS from the statutory minimum of thirty (30) days will be considered timely. and will expire SIX (6) MONTHS from the mailing date of this communication.			
earned p	patent term adjustment. See 37 CFN 1.704(a).				
Status 1)	Responsive to communication(s) filed on	· .			
2-1	This action is FINAL 2b) X This act	tion is non-final.			
3) 🗆	The second in the condition for allowance except for formal matters, prosecution as to the merits is				
Disposit	tion of Claims	is/are pending in the application.			
4) 💢	Claim(s) 43-68	is/are pending in the application.			
4	a) Of the above, claim(s)	is/are withdrawn from consideration.			
5) 🗆	Claim(s)	IS/ate allowed.			
6) 🗆	Claim(s)	IS/are rejected.			
7) 🗆	Claim In	15/d/6-00/00/00 to.			
8) 🔽	Claims 43-68	are subject to restriction and/or election requirement.			
	ation Papers				
9) 🗆					
10)□	The drawing(s) filed on is/ar	re a) accepted or b) objected to by the Examiner.			
11)□	Applicant may not request that any objection to the The proposed drawing correction filed on	is: a) approved b) disapproved by the Examiner.			
	If approved, corrected drawings are required in repl	y to this Office action.			
12)		miner.			
13)□		priority under 35 U.S.C. § 119(a)-(d) or (f).			
a)	☐ All b)☐ Some* c)☐ None of:	hous been received			
	1. Certified copies of the priority documents h	have been received in Application No			
	2. Certified copies of the priority documents in	documents have been received in this National Stage			
*	application from the international be	the certified copies not received.			
14)	Acknowledgement is made of a claim for domes	stic priority under 35 U.S.C. § 119(e).			
1	The translation of the foreign language provision	onal application has been received.			
15)[Acknowledgement is made of a claim for domes	stic priority under 35 U.S.C. §§ 120 and/or 121.			
	hment(s)	4) Interview Summary (PTO-413) Paper No(s).			
	Notice of References Cited (PTO-892)	5) Notice of Informal Patent Application (PTO-152)			
	Notice of Draftsperson's Patent Drawing Review (PTO-948)	6) Other:			
3)	Information Disclosure Statement(s) (PTO-1449) Paper No(s).	· · · · · · · · · · · · · · · · · · ·			

Art Unit: 1647

DETAILED ACTION

Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claim 43, 46, 49, 50, 53, drawn to a polypeptide comprising the amino acid sequence of SEQ ID NO:4, classified in class 530, subclass 399, for example.
 - II. Claim 44, 47, 49, 51, 54, drawn to a polypeptide comprising the amino acid sequence of SEQ ID NO:8, classified in class 530, subclass 399, for example.
 - III. Claim 45, 48, 49, 52, 55, drawn to a polypeptide comprising the amino acid sequence of SEQ ID NO:10, classified in class 530, subclass 399, for example.
 - IV. Claim 56, drawn to an antibody to a polypeptide comprising the amino acid sequence of SEQ ID NO:4 classified in class 530, subclass 387.1, for example.
 - V. Claim 57, drawn to an antibody to a polypeptide comprising the amino acid sequence of SEQ ID NO:8 classified in class 530, subclass 387.1, for example.
 - VI. Claim 58, drawn to an antibody to a polypeptide comprising the amino acid sequence of SEQ ID NO:10 classified in class 530, subclass 387.1, for example.
 - VII. Claims 59-60, drawn to a nucleic acid which hybridizes to SEQ ID NO:3 and encodes a VEGF-B molecule, classified in class 536, subclass 23.5, for example.
 - VIII. Claims 61, 65, drawn to a nucleic acid molecule which encodes an amino acid sequence of SEQ ID NO:4, classified in class 536, subclass 23.5, for example.
 - IX. Claims 62, 66, drawn to a nucleic acid molecule which encodes an amino acid sequence of SEQ ID NO:6, classified in class 536, subclass 23.5, for example.
 - X. Claims 63, 67 drawn to a nucleic acid molecule which encodes an amino acid sequence of SEQ ID NO:8, classified in class 536, subclass 23.5, for example.
 - XI. Claims 64, 68, drawn to a nucleic acid molecule which encodes an amino acid sequence of SEQ ID NO:10, classified in class 536, subclass 23.5, for example.

Art Unit: 1647

2. The inventions are distinct, each from the other because of the following reasons:

- 3. Inventions (I-III) and (IV-VI) are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polypeptides of Groups I-III could be used in an entirely different method, such as in a method of cell stimulation, rather than in a method of making the antibodies.
- 4. Inventions (I-III) and (VIII-XI) are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the nucleic acids of Groups VIII-XI could be used for an entirely different purpose such as in methods of detection, rather than for the production of the polypeptides of Groups I-III.
- 5. Inventions I-XI are also unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together, or they have different modes of operation, or they have different functions, or they have different effects. (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are directed to chemically distinct compounds which can be made and used without each other. Such distinction is evidenced by the specific structure of each compound. Furthermore, the inventions of Groups I-XI lack a common utility which is

Art Unit: 1647

based upon a common special technical feature which is disclosed as being responsible for the common utility.

- 6. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and/or the necessity for non-coextensive literature searches, restriction for examination purposes as indicated is proper.
- 7. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Christine J. Saoud, Ph.D., whose telephone number is (703) 305-7519. The Examiner can normally be reached on Monday to Thursday from 8AM to 2PM. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Gary Kunz, can be reached on (703) 308-4623.

Certain papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1 (CM1). The faxing of such papers must conform with the notices

Art Unit: 1647

published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. §§ 1.6(d) and 1.8). NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by Applicant or Applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers.

Official papers filed by fax should be directed to (703) 872-9306. If this number is out of service, please call the Group receptionist for an alternate number. Official papers filed After Final rejection filed by fax should be directed to (703) 872-9307.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

CHRISTINE J. SAOUD
PRIMARY EXAMINER

(histin) Saoud

.